Baseline characteristics of immune mediated inflammatory disease cohorts
| Variables | RA | IBD | PsO-PsA-AS | |||
|---|---|---|---|---|---|---|
| TNFI (n=24 384) | Non-biological DMARD (n=11 828) | TNFI (n=3850) | Non-biological DMARD (n=6867) | TNFI (n=5090) | Non-biological DMARD (n=7047) | |
| Age, mean (SD), years | 57.73 (14.53) | 58.47 (14.27) | 40.39 (16.13) | 40.38 (17.80) | 48.82 (15.33) | 52.19 (16.82) |
| Female | 20 955 (85.9) | 10 205 (86.3) | 2559 (66.5) | 4330 (63.1) | 2854 (56.1) | 4331 (61.4) |
| Race | ||||||
| White | 15 244 (62.5) | 7340 (62.0) | 3010 (78.2) | 5075 (73.9) | 3716 (73.0) | 4986 (70.7) |
| Black | 3927 (16.1) | 1831 (15.5) | 586 (15.2) | 993 (14.5) | 357 (7.0) | 576 (8.2) |
| Other | 5212 (21.4) | 2659 (22.5) | 254 (6.6) | 799 (11.6) | 1017 (20.0) | 1489 (21.1) |
| Nursing home resident | 992 (4.1) | 493 (4.2) | 99 (2.6) | 167 (2.4) | 146 (2.9) | 334 (4.7) |
| ≥1 Hospitalisation during baseline* | 6995 (28.7) | 3305 (27.9) | 2133 (55.4) | 3387 (49.3) | 1042 (20.5) | 1613 (22.9) |
| Charlson–Deyo comorbidity score†, mean (SD) | 1.72 (1.13) | 1.73 (1.17) | 0.51 (0.95) | 0.47 (0.90) | 0.74 (1.13) | 0.79 (1.18) |
| ≥1 Inflammatory marker tested | 8955 (36.7) | 4380 (37.0) | 1094 (28.4) | 2058 (30.0) | 1045 (20.5) | 1370 (19.4) |
| Mean glucocorticoid use, daily prednisone equivalent doses | ||||||
| None | 9732 (39.9) | 5079 (42.9) | 1714 (44.5) | 2773 (40.4) | 4038 (79.3) | 5461 (77.5) |
| (0–<5 mg) | 7552 (31.0) | 3650 (30.9) | 609 (15.8) | 973 (14.2) | 700 (13.8) | 1162 (16.5) |
| (5–10 mg) | 4604 (18.9) | 2045 (17.3) | 594 (15.4) | 1167 (17.0) | 196 (3.9) | 153 (2.2) |
| (>10 mg) | 2495 (10.2) | 1056 (8.9) | 933 (24.2) | 1954 (28.5) | 156 (3.1) | 275 (3.9) |
| Any orthopaedic surgery | 1752 (7.2) | 633 (5.4) | 66 (1.7) | 85 (1.2) | 189 (3.7) | 177 (2.5) |
| Any intra-articular injection | 8607 (35.3) | 3596 (30.4) | 198 (5.1) | 259 (3.8) | 695 (13.7) | 817 (11.6) |
| Comorbidites | ||||||
| COPD | 3241 (13.3) | 1584 (13.4) | 311 (8.1) | 484 (7.0) | 502 (9.9) | 870 (12.3) |
| Cerebrovascular disease | 947 (3.9) | 419 (3.5) | 82 (2.1) | 118 (1.7) | 116 (2.3) | 248 (3.5) |
| Diabetes | 4618 (18.9) | 2266 (19.2) | 336 (8.7) | 541 (7.9) | 1021 (20.1) | 1337 (19.0) |
| Obesity | 2153 (8.8) | 1227 (10.4) | 276 (7.2) | 676 (9.8) | 697 (13.7) | 953 (13.5) |
| History of cancer | 1795 (7.3) | 956 (7.9) | 174 (4.4) | 352 (4.8) | 277 (5.3) | 595 (7.4) |
| ≥1 Antibiotic dispensed‡ | 16 627 (68.2) | 7234 (61.1) | 2775 (72.1) | 4419 (64.4) | 3178 (62.4) | 4075 (57.8) |
| Medication initiated | ||||||
| Adalimumab | 5888 (24.1) | – | 118 (3.1) | – | 294 (5.8) | – |
| Etanercept | 10 283 (42.2) | – | – | – | 4270 (83.9) | – |
| Infliximab | 8212 (33.7) | – | 3732 (96.9) | – | 526 (10.3) | – |
| Hydroxychloroquine | – | 5730 (48.4) | – | – | – | 569 (8.1) |
| Leflunomide | 4569 (38.6) | 133 (1.9) | ||||
| Sulfasalazine | – | 1531 (12.9) | – | – | – | 858 (12.2) |
| Mercaptopurine | 3475 (50.6) | – | ||||
| Methotrexate | – | – | – | – | 5491 (77.9) | |
| Azathioprine | – | – | – | 3392 (49.4) | ||
*Hospitalisation for any reason.
†The Charlson–Deyo comorbidity index provides an estimate of disease severity and comorbidities for a given patient.
‡Any antibiotic prescription.
COPD, chronic obstructive pulmonary disease; DMARD, disease-modifying anti rheumatic drug; IBD, inflammatory bowel disease; PsO-PsA-AS, psoriasis, psoriatic arthritis, ankylosing spondylitis; RA, rheumatoid arthritis; SABER, Safety Assessment of Biologic Therapy; TNFI, tumour necrosis factor α inhibitor.